JP6912039B2 - 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用 - Google Patents
置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用 Download PDFInfo
- Publication number
- JP6912039B2 JP6912039B2 JP2018506999A JP2018506999A JP6912039B2 JP 6912039 B2 JP6912039 B2 JP 6912039B2 JP 2018506999 A JP2018506999 A JP 2018506999A JP 2018506999 A JP2018506999 A JP 2018506999A JP 6912039 B2 JP6912039 B2 JP 6912039B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- mmol
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c([n](*)c1c2*)nc1c(*)c(*)c2C(C(*)=C1*)=C(*)N(*)C1=O Chemical compound *c([n](*)c1c2*)nc1c(*)c(*)c2C(C(*)=C1*)=C(*)N(*)C1=O 0.000 description 4
- VHJMPHDWNNQOKM-UHFFFAOYSA-N CC1=CC(c(cc2)cc(NCCOC(F)(F)F)c2N)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc(NCCOC(F)(F)F)c2N)=CN(C)C1=O VHJMPHDWNNQOKM-UHFFFAOYSA-N 0.000 description 2
- LZNWLEPJPMWRAU-UHFFFAOYSA-N CC1=CC(c(cc2)cc(NCCOCC(F)(F)F)c2[N+]([O-])=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc(NCCOCC(F)(F)F)c2[N+]([O-])=O)=CN(C)C1=O LZNWLEPJPMWRAU-UHFFFAOYSA-N 0.000 description 2
- MKZMIAGKYGHZTF-KRWDZBQOSA-N CCO[C@@H](C)CNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1NC(C(CC1)CCC1(F)F)=O Chemical compound CCO[C@@H](C)CNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1NC(C(CC1)CCC1(F)F)=O MKZMIAGKYGHZTF-KRWDZBQOSA-N 0.000 description 2
- PXZKFECAINECTN-UHFFFAOYSA-N CC(C)(CC(c(cc1)cc(NCCOC(F)(F)F)c1N)=CN1C)C1=O Chemical compound CC(C)(CC(c(cc1)cc(NCCOC(F)(F)F)c1N)=CN1C)C1=O PXZKFECAINECTN-UHFFFAOYSA-N 0.000 description 1
- XSEWRPXQLCGDQL-NTEUORMPSA-N CC(C)OC/C(/C)=N/c(cc(cc1)Br)c1[N+]([O-])=O Chemical compound CC(C)OC/C(/C)=N/c(cc(cc1)Br)c1[N+]([O-])=O XSEWRPXQLCGDQL-NTEUORMPSA-N 0.000 description 1
- RETZKOVMQQKTET-UHFFFAOYSA-N CC(C)OCCNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1N Chemical compound CC(C)OCCNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1N RETZKOVMQQKTET-UHFFFAOYSA-N 0.000 description 1
- XCYVXDCJCCRFQM-UHFFFAOYSA-N CC(C)OCCNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1[N+]([O-])=O Chemical compound CC(C)OCCNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1[N+]([O-])=O XCYVXDCJCCRFQM-UHFFFAOYSA-N 0.000 description 1
- PHCNFIFMPMPDQX-CQSZACIVSA-N CC(C)OC[C@@H](C)Nc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1[N+]([O-])=O Chemical compound CC(C)OC[C@@H](C)Nc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1[N+]([O-])=O PHCNFIFMPMPDQX-CQSZACIVSA-N 0.000 description 1
- CHZCPIPXCVHABA-UHFFFAOYSA-N CC1=CC(c(cc2)cc(NCCC(F)(F)F)c2[N+]([O-])=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc(NCCC(F)(F)F)c2[N+]([O-])=O)=CN(C)C1=O CHZCPIPXCVHABA-UHFFFAOYSA-N 0.000 description 1
- VAYRDQOBRYXFLR-UHFFFAOYSA-N CC1=CC(c(cc2)cc(NCCOC(F)(F)F)c2NC(C2CCOCC2)=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc(NCCOC(F)(F)F)c2NC(C2CCOCC2)=O)=CN(C)C1=O VAYRDQOBRYXFLR-UHFFFAOYSA-N 0.000 description 1
- WMNNABKFYKETDN-GOSISDBHSA-N CC1=CC(c(cc2)cc(NCCOC(F)(F)F)c2NC([C@@H]2OCCC2)=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc(NCCOC(F)(F)F)c2NC([C@@H]2OCCC2)=O)=CN(C)C1=O WMNNABKFYKETDN-GOSISDBHSA-N 0.000 description 1
- WXAKFDPGXRUIKH-UHFFFAOYSA-N CC1=CC(c(cc2)cc(NCCOCC(F)(F)F)c2N)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc(NCCOCC(F)(F)F)c2N)=CN(C)C1=O WXAKFDPGXRUIKH-UHFFFAOYSA-N 0.000 description 1
- ZEWABZLDZQPDSD-UHFFFAOYSA-N CC1=CC(c(cc2)cc3c2nc(C2CC2)[n]3CCOC)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc3c2nc(C2CC2)[n]3CCOC)=CN(C)C1=O ZEWABZLDZQPDSD-UHFFFAOYSA-N 0.000 description 1
- MGUONTZTOXWFRF-UHFFFAOYSA-N CC1=CC(c(cc2)cc3c2nc(C2CCCCC2)[n]3CCOC)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)cc3c2nc(C2CCCCC2)[n]3CCOC)=CN(C)C1=O MGUONTZTOXWFRF-UHFFFAOYSA-N 0.000 description 1
- MYXRAGJJJUOGSZ-UHFFFAOYSA-N CC1=CC(c(cc2NCCOC)ccc2N)=CN(C)C1=O Chemical compound CC1=CC(c(cc2NCCOC)ccc2N)=CN(C)C1=O MYXRAGJJJUOGSZ-UHFFFAOYSA-N 0.000 description 1
- IOPDSZLMUOSZHZ-UHFFFAOYSA-N CCOCCNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1N Chemical compound CCOCCNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1N IOPDSZLMUOSZHZ-UHFFFAOYSA-N 0.000 description 1
- ZFRDNEQQDDWQHJ-KRWDZBQOSA-N CCO[C@@H](C)C[n]1c(cc(cc2)C(C=C3C)=CN(C)C3=O)c2nc1C(CC1)CCC1(F)F Chemical compound CCO[C@@H](C)C[n]1c(cc(cc2)C(C=C3C)=CN(C)C3=O)c2nc1C(CC1)CCC1(F)F ZFRDNEQQDDWQHJ-KRWDZBQOSA-N 0.000 description 1
- KUBZLZAZMNELCG-MRVPVSSYSA-N CCO[C@H](C)CNc(cc(cc1)Br)c1N Chemical compound CCO[C@H](C)CNc(cc(cc1)Br)c1N KUBZLZAZMNELCG-MRVPVSSYSA-N 0.000 description 1
- QMWWEMLJYVJWOS-MRVPVSSYSA-N CCO[C@H](C)CNc(cc(cc1)Br)c1[N+]([O-])=O Chemical compound CCO[C@H](C)CNc(cc(cc1)Br)c1[N+]([O-])=O QMWWEMLJYVJWOS-MRVPVSSYSA-N 0.000 description 1
- BBUARUBIXANZIS-CYBMUJFWSA-N CCO[C@H](C)CNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1N Chemical compound CCO[C@H](C)CNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1N BBUARUBIXANZIS-CYBMUJFWSA-N 0.000 description 1
- OSBPHVXQBVVYMK-OAHLLOKOSA-N CCO[C@H](C)CNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1NC(C(C1)CC1(F)F)=O Chemical compound CCO[C@H](C)CNc(cc(cc1)C(C=C2C)=CN(C)C2=O)c1NC(C(C1)CC1(F)F)=O OSBPHVXQBVVYMK-OAHLLOKOSA-N 0.000 description 1
- WIZDANJNJRRRQZ-INIZCTEOSA-N C[C@@H](COC)[n]1c(cc(cc2)C(C=C3C)=CN(C)C3=O)c2nc1C(CC1)CCC1(F)F Chemical compound C[C@@H](COC)[n]1c(cc(cc2)C(C=C3C)=CN(C)C3=O)c2nc1C(CC1)CCC1(F)F WIZDANJNJRRRQZ-INIZCTEOSA-N 0.000 description 1
- RGFKQNCZZJVQFC-UHFFFAOYSA-N Cc([n](CCOC(F)(F)F)c1c2)nc1ccc2C(C=C1C)=CN(C)C1=O Chemical compound Cc([n](CCOC(F)(F)F)c1c2)nc1ccc2C(C=C1C)=CN(C)C1=O RGFKQNCZZJVQFC-UHFFFAOYSA-N 0.000 description 1
- ILYVDFJXCZLQOG-UHFFFAOYSA-N Cc1nc(ccc(Br)c2)c2[n]1CCOC(F)(F)F Chemical compound Cc1nc(ccc(Br)c2)c2[n]1CCOC(F)(F)F ILYVDFJXCZLQOG-UHFFFAOYSA-N 0.000 description 1
- VOJANFHOLSIPBC-UHFFFAOYSA-N FC(CC1)(CCC1c([nH]c1c2)nc1ccc2Br)F Chemical compound FC(CC1)(CCC1c([nH]c1c2)nc1ccc2Br)F VOJANFHOLSIPBC-UHFFFAOYSA-N 0.000 description 1
- GXZZKJRWIAZFFL-UHFFFAOYSA-N [O-][N+](c(ccc(Br)c1)c1NCCOCC(F)(F)F)=O Chemical compound [O-][N+](c(ccc(Br)c1)c1NCCOCC(F)(F)F)=O GXZZKJRWIAZFFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204178P | 2015-08-12 | 2015-08-12 | |
| US62/204,178 | 2015-08-12 | ||
| US201662358101P | 2016-07-04 | 2016-07-04 | |
| US62/358,101 | 2016-07-04 | ||
| PCT/CA2016/050952 WO2017024412A1 (en) | 2015-08-12 | 2016-08-12 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522925A JP2018522925A (ja) | 2018-08-16 |
| JP2018522925A5 JP2018522925A5 (https=) | 2019-09-26 |
| JP6912039B2 true JP6912039B2 (ja) | 2021-07-28 |
Family
ID=57982882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506999A Active JP6912039B2 (ja) | 2015-08-12 | 2016-08-12 | 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10703740B2 (https=) |
| EP (1) | EP3334719B1 (https=) |
| JP (1) | JP6912039B2 (https=) |
| KR (1) | KR102784592B1 (https=) |
| CN (2) | CN114605387A (https=) |
| AU (2) | AU2016305515A1 (https=) |
| CA (1) | CA2994478C (https=) |
| ES (1) | ES2904258T3 (https=) |
| IL (1) | IL257340B2 (https=) |
| MX (1) | MX382832B (https=) |
| WO (1) | WO2017024412A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102784592B1 (ko) * | 2015-08-12 | 2025-03-19 | 에피제네틱스, 인크. | 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도 |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| JP7165501B2 (ja) * | 2017-03-15 | 2022-11-04 | 住友ファーマ株式会社 | 新規ベンズイミダゾール化合物からなる医薬 |
| WO2018207882A1 (ja) * | 2017-05-12 | 2018-11-15 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| WO2020093162A1 (en) * | 2018-11-07 | 2020-05-14 | Neomed Institute | Treatment of bet inhibitor-resistant cancers and other diseases responsive to dual bet and cbp/ep300 inhibition therapy |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| CN112174945B (zh) * | 2019-07-02 | 2022-06-07 | 四川大学 | 具有抗癌作用的吲唑类化合物及其制备方法和用途 |
| CN115232074A (zh) * | 2022-08-22 | 2022-10-25 | 湖南复瑞生物医药技术有限责任公司 | 一种1-烷基取代-2-甲基-5-溴苯并咪唑的合成方法 |
| WO2024249796A2 (en) * | 2023-06-02 | 2024-12-05 | Epigenetix, Inc. | Extended and delayed release compositions of substituted benzimidazoles |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550166A (en) | 1984-05-21 | 1985-10-29 | American Cyanamid Company | (Pyridinyl)-1,2,4-triazolo[4,3-a]pyridines |
| US4785005A (en) | 1986-06-25 | 1988-11-15 | Rorer Pharmaceutical Corporation | 6-(6-alkylpyridone)-carbostyril compounds and their cardiotonic uses |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| DE4237656A1 (de) * | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
| US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2341409A1 (en) | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
| MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| BRPI0417674A (pt) | 2003-12-18 | 2007-03-20 | Pfizer Prod Inc | método para tratar a inflamação aguda em animais, com inibidores de quinase map p38 |
| ES2328047T3 (es) | 2004-03-19 | 2009-11-06 | Warner-Lambert Company Llc | Derivados de imidazopiridina e imidazopirimidina como agentes antibacterianos. |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| MX2009008531A (es) * | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| AR068877A1 (es) | 2007-10-17 | 2009-12-09 | Novartis Ag | Derivados heterociclicos de imidazol |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2011060235A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Imidazole derivatives and methods of use thereof |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| UY34750A (es) * | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| BR112014030940B1 (pt) | 2012-06-11 | 2022-09-06 | UCB Biopharma SRL | Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos |
| AU2012382373A1 (en) | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| JP6430383B2 (ja) | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN105229002A (zh) | 2012-12-20 | 2016-01-06 | 拜耳医药股份有限公司 | 抑制bet蛋白的二氢吡啶并吡嗪酮 |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| CA2904364A1 (en) | 2013-03-15 | 2014-09-25 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
| ES2635003T3 (es) | 2013-07-09 | 2017-10-02 | Bayer Pharma Aktiengesellschaft | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas inhibidoras de proteína BET |
| US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| WO2015049629A1 (en) | 2013-10-01 | 2015-04-09 | Piramal Enterprises Limited | Imidazoquinoline compounds as bromodomain inhibitors |
| SG10201804471PA (en) | 2013-10-18 | 2018-07-30 | Celgene Quanticel Research Inc | Bromodomain inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| EP3089970B1 (en) | 2013-12-09 | 2018-10-17 | AbbVie Inc. | Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors |
| HUE041546T2 (hu) | 2014-01-09 | 2019-05-28 | Orion Corp | Biciklusos heterociklusos származékvegyületek mint bromo doméninhibitorok |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| WO2016077656A2 (en) | 2014-11-13 | 2016-05-19 | Convergene Llc | Methods and compositions for inhibition of bromodomain and extraterminal proteins |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| WO2016097870A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Substituted bicyclic compounds as bromodomain inhibitors |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| GB201503720D0 (en) | 2015-03-05 | 2015-04-22 | Glaxosmithkline Ip No 2 Ltd | Chemical compound |
| GB201504689D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| KR102784592B1 (ko) * | 2015-08-12 | 2025-03-19 | 에피제네틱스, 인크. | 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도 |
-
2016
- 2016-08-12 KR KR1020187006581A patent/KR102784592B1/ko active Active
- 2016-08-12 CA CA2994478A patent/CA2994478C/en active Active
- 2016-08-12 CN CN202111621671.6A patent/CN114605387A/zh active Pending
- 2016-08-12 CN CN201680059249.7A patent/CN108137539B/zh active Active
- 2016-08-12 ES ES16834372T patent/ES2904258T3/es active Active
- 2016-08-12 US US15/751,801 patent/US10703740B2/en active Active
- 2016-08-12 IL IL257340A patent/IL257340B2/en unknown
- 2016-08-12 MX MX2018001756A patent/MX382832B/es unknown
- 2016-08-12 EP EP16834372.1A patent/EP3334719B1/en active Active
- 2016-08-12 AU AU2016305515A patent/AU2016305515A1/en not_active Abandoned
- 2016-08-12 WO PCT/CA2016/050952 patent/WO2017024412A1/en not_active Ceased
- 2016-08-12 JP JP2018506999A patent/JP6912039B2/ja active Active
-
2020
- 2020-05-22 US US16/881,803 patent/US11365186B2/en active Active
-
2021
- 2021-01-12 AU AU2021200147A patent/AU2021200147B2/en active Active
-
2022
- 2022-05-13 US US17/743,792 patent/US11981657B2/en active Active
-
2024
- 2024-04-08 US US18/629,321 patent/US20240425481A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210107893A1 (en) | 2021-04-15 |
| KR20180039669A (ko) | 2018-04-18 |
| EP3334719B1 (en) | 2021-09-15 |
| CA2994478C (en) | 2023-10-03 |
| HK1256752A1 (en) | 2019-10-04 |
| US20180237417A1 (en) | 2018-08-23 |
| IL257340A (en) | 2018-03-29 |
| CN114605387A (zh) | 2022-06-10 |
| EP3334719A1 (en) | 2018-06-20 |
| CN108137539B (zh) | 2022-01-11 |
| US11365186B2 (en) | 2022-06-21 |
| EP3334719A4 (en) | 2019-02-06 |
| CA2994478A1 (en) | 2017-02-16 |
| US20240425481A1 (en) | 2024-12-26 |
| US20230120413A1 (en) | 2023-04-20 |
| US10703740B2 (en) | 2020-07-07 |
| IL257340B1 (en) | 2023-06-01 |
| BR112018002547A2 (pt) | 2018-09-18 |
| JP2018522925A (ja) | 2018-08-16 |
| ES2904258T3 (es) | 2022-04-04 |
| MX2018001756A (es) | 2018-09-06 |
| KR102784592B1 (ko) | 2025-03-19 |
| CN108137539A (zh) | 2018-06-08 |
| AU2021200147A1 (en) | 2021-03-18 |
| WO2017024412A1 (en) | 2017-02-16 |
| AU2016305515A1 (en) | 2018-03-08 |
| US11981657B2 (en) | 2024-05-14 |
| MX382832B (es) | 2025-03-13 |
| AU2021200147B2 (en) | 2022-09-08 |
| IL257340B2 (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6912039B2 (ja) | 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用 | |
| JP6154004B2 (ja) | ブロモドメイン阻害剤のベンゾ［ｃ］イソオキサゾロアゼピン及びその使用 | |
| JP2016519660A (ja) | ブロモドメイン阻害剤としてのオキサゾロ［５，４−ｃ］キノリン−２−オン化合物 | |
| JP2017511801A (ja) | ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体 | |
| WO2018205938A1 (zh) | Parp抑制剂、其药物组合物、制备方法和应用 | |
| US20200299262A1 (en) | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals | |
| US10836742B2 (en) | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals | |
| BR112018002547B1 (pt) | Benzimidazóis substituídos, seus usos, e composição farmacêutica | |
| HK1256752B (en) | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190813 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190813 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190919 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210113 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210608 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210624 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6912039 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |